BEIZRAY Drug Patent Profile
Which patents cover Beizray, and what generic alternatives are available?
Beizray is a drug marketed by Zhuhai and is included in one NDA. There are three patents protecting this drug.
The generic ingredient in BEIZRAY is docetaxel. There is one drug master file entry for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the docetaxel profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Beizray
A generic version of BEIZRAY was approved as docetaxel by HOSPIRA INC on March 8th, 2011.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for BEIZRAY?
- What are the global sales for BEIZRAY?
- What is Average Wholesale Price for BEIZRAY?
Summary for BEIZRAY
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| Patent Applications: | 6,676 |
| What excipients (inactive ingredients) are in BEIZRAY? | BEIZRAY excipients list |
| DailyMed Link: | BEIZRAY at DailyMed |
Pharmacology for BEIZRAY
| Drug Class | Microtubule Inhibitor |
| Physiological Effect | Microtubule Inhibition |
US Patents and Regulatory Information for BEIZRAY
BEIZRAY is protected by eleven US patents.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zhuhai | BEIZRAY | docetaxel | SOLUTION;INTRAVENOUS | 218711-002 | Dec 10, 2025 | RX | Yes | Yes | 12,090,134 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Zhuhai | BEIZRAY | docetaxel | SOLUTION;INTRAVENOUS | 218711-001 | Oct 23, 2024 | RX | Yes | Yes | 11,419,842 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Zhuhai | BEIZRAY | docetaxel | SOLUTION;INTRAVENOUS | 218711-002 | Dec 10, 2025 | RX | Yes | Yes | 11,419,842 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Zhuhai | BEIZRAY | docetaxel | SOLUTION;INTRAVENOUS | 218711-001 | Oct 23, 2024 | RX | Yes | Yes | 12,090,135 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Zhuhai | BEIZRAY | docetaxel | SOLUTION;INTRAVENOUS | 218711-001 | Oct 23, 2024 | RX | Yes | Yes | 12,090,134 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Zhuhai | BEIZRAY | docetaxel | SOLUTION;INTRAVENOUS | 218711-002 | Dec 10, 2025 | RX | Yes | Yes | 12,090,135 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for BEIZRAY
See the table below for patents covering BEIZRAY around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| China | 110062622 | 多西他赛和人血清白蛋白的中性pH组合物 (NEUTRAL PH COMPOSITIONS OF DOCETAXEL AND HUMAN SERUM ALBUMIN) | ⤷ Start Trial |
| China | 115487312 | 多西他赛和人血清白蛋白的中性pH组合物 (Neutral pH compositions of docetaxel and human serum albumin) | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2018081520 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for BEIZRAY
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0253738 | C960002 | Netherlands | ⤷ Start Trial | PRODUCT NAME: DOCETAXEL, DESGEWENST IN DE VORM VAN EEN TRIHYDRAAT; REGISTRATION NO/DATE: EU/1/95/002/001 - EU/1/95/002/002 19951127 |
| 1667986 | 92172 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: SOLVAT ACETONIQUE DU CABAZITAXEL, OU DESIGNE SOLVAT ACETONIQUE DU DIMETHOXY DOCETAXEL OU SOLVAT ACETONIQUE DU (2R,3S)-3-TERT-BUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE DE 4-ACETOXY-2A-BENZOYLOXY-5BETA,20-EPOXY-1-HYDROXY-7BETA,10A-DIMETHOXY-9-OXO-TAX-11-ENE-13A-YLE(ACETONATE DU CABAZITAXEL) |
| 1667986 | 28/2013 | Austria | ⤷ Start Trial | PRODUCT NAME: DIMETHOXYDOCETAXEL-ACETONSOLVAT (CABAZITAXEL-ACETONSOLVAT); REGISTRATION NO/DATE: EU/1/11/676/001 20110317 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
DrugChatter Q&A for BEIZRAY
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch